Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1990 1
1991 2
1992 2
1993 1
1995 2
1996 2
1998 3
1999 3
2000 5
2001 4
2002 5
2003 5
2004 5
2005 2
2006 5
2007 4
2008 4
2009 10
2010 6
2011 2
2012 3
2013 8
2014 5
2015 9
2016 4
2017 5
2018 4
2019 2
2020 3
2021 5
2022 8
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Zinman B, et al. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. N Engl J Med. 2015. PMID: 26378978 Free article. Clinical Trial.
The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the placebo group (hazard ratio in the empagliflozin group, 0.86; 95.02% confidence interval, 0.74 to 0.99; P=0.04 for superiority). There …
The primary outcome occurred in 490 of 4687 patients (10.5%) in the pooled empagliflozin group and in 282 of 2333 patients (12.1%) in the pl …
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Kronenberg F, et al. Eur Heart J. 2022 Oct 14;43(39):3925-3946. doi: 10.1093/eurheartj/ehac361. Eur Heart J. 2022. PMID: 36036785 Free PMC article.
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.
Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada-Shiba M, Hudgins LC, Kayikcioglu M, Masana L, Parhofer KG, Roeters van Lennep JE, Santos RD, Stroes ESG, Watts GF, Wiegman A, Stock JK, Tokgözoğlu LS, Catapano AL, Ray KK. Cuchel M, et al. Eur Heart J. 2023 Jul 1;44(25):2277-2291. doi: 10.1093/eurheartj/ehad197. Eur Heart J. 2023. PMID: 37130090 Free PMC article.
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky ML, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Kronenberg F, et al. Atherosclerosis. 2023 Jun;374:107-120. doi: 10.1016/j.atherosclerosis.2023.04.012. Epub 2023 Apr 28. Atherosclerosis. 2023. PMID: 37188555 Free article. Review.
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021 Nov 6;398(10312):1713-1725. doi: 10.1016/S0140-6736(21)01122-3. Epub 2021 Sep 7. Lancet. 2021. PMID: 34506743
Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular risk factors and cardiovascular diseases (all p<0.001). INTERPRETATION: Familial hypercholesterolaemia is diagnosed late. ...
Compared with index cases, patients who were non-index cases were younger, with lower LDL cholesterol and lower prevalence of cardiovascular …
Differentiating EPA from EPA/DHA in cardiovascular risk reduction.
Toth PP, Chapman MJ, Parhofer KG, Nelson JR. Toth PP, et al. Am Heart J Plus. 2022 May 28;17:100148. doi: 10.1016/j.ahjo.2022.100148. eCollection 2022 May. Am Heart J Plus. 2022. PMID: 38559888 Free PMC article. Review.
In contrast, the Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT), which employed high-dose (4 g) purified EPA, demonstrated a 25% reduction in atherosclerotic cardiovascular disease-related events compared with placebo (hazard ratio 0.75; 95 …
In contrast, the Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT), which employed high-dose (4 g) puri …
[Clinical evaluation of the hip joint after implantation of cementless Mittelmeier type and Parhofer-Monch type hip prosthesis].
Grzegorzewski A, Synder M, Witoński D. Grzegorzewski A, et al. Chir Narzadow Ruchu Ortop Pol. 2000;65(1):39-45. Chir Narzadow Ruchu Ortop Pol. 2000. PMID: 10838767 Polish.
The follow-up ranged from 24 to 143 months (average 61.2 months). The P-M prothesis was implanted in 53 hips, the P-M "Plasmapore" prothesis in 42 patients, Mittelmeier Autophor 900 prothesis in 49 patients and the Mittelmeier Autophor 900S prothesis in 7 patients. …
The follow-up ranged from 24 to 143 months (average 61.2 months). The P-M prothesis was implanted in 53 hips, the P-M "Plasmap …
Diagnostic algorithm for familial chylomicronemia syndrome.
Stroes E, Moulin P, Parhofer KG, Rebours V, Löhr JM, Averna M. Stroes E, et al. Atheroscler Suppl. 2017 Jan;23:1-7. doi: 10.1016/j.atherosclerosissup.2016.10.002. Epub 2016 Dec 18. Atheroscler Suppl. 2017. PMID: 27998715 Free article.
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus.
Parhofer KG, Birkenfeld AL, Krone W, Lehrke M, Marx N, Merkel M, Schütt KS, Zirlik A, Müller-Wieland D. Parhofer KG, et al. Exp Clin Endocrinol Diabetes. 2022 Sep;130(S 01):S117-S122. doi: 10.1055/a-1624-3572. Epub 2022 Mar 31. Exp Clin Endocrinol Diabetes. 2022. PMID: 35359011 No abstract available.
121 results